Objective: We studied the prevalence of asthma and allergy in non-elite marathon runners and investigated the effects of probiotic supplementation on allergic inflammatory markers. Methods: Asthma and allergies were surveyed by questionnaire, and blood eosinophils, serum eosinophil cationic protein (ECP), total IgE, and Phadiatop s were measured in 141 Finnish marathon runners who took part in the Helsinki City Marathon. They were also randomized to receive either Lactobacillus GG (LGG) or placebo during the 3 months of the pollen season prior to the marathon. Results: Lifetime prevalence of physician-diagnosed asthma was 4.3% (six out of 139 athletes), of allergic rhinitis 17.3% (24/139), of food allergy 5.0% (7/139), and of atopic eczema 4.3% (6/139). Prevalence of atopy was 31% (35/112), and 21% (24/112) of the athletes were sensitized to birch pollen. Asthma or allergy medication was used by 20% (28/139) of the athletes. During pollen season, serum ECP increased significantly in all athletes, and total IgE and Phadiatop s in atopics. The marathon induced a significant eosinopenia but had no effect on serum ECP or total IgE. No differences in changes were seen between groups receiving LGG or placebo. Conclusion: Non-elite marathon runners have asthma and allergies similar to Finnish general population.
Conclusion: Non-elite marathon runners have asthma and allergies similar to Finnish general population.
LGG supplementation did not prevent the increase of allergic markers during the pollen season, or the eosinopenia induced by the marathon. & 2006 Elsevier Ltd. All rights reserved.
Background
Evidence suggests an increased risk of asthma and bronchial hyperresponsiveness in elite athletes. [1] [2] [3] Plausible biological explanations include type of sports, training environment and athlete's atopic background. [4] [5] [6] Strenuous exercise, such as a marathon run, can lead to a temporary immunosuppression, with impairment of both innate and acquired immune responses. 7 Several nutritional countermeasures to this immunosuppression have been tried without success. 8 Probiotic lactic acid bacteria can be defined as ''a live microbial food ingredient that is beneficial to health''. 9 In addition to the effects on non-immunologic gut defence these bacteria promote both innate and acquired immune responses, and their protective role in allergy development has also been recently suggested. 10, 11 ARTICLE IN PRESS Figure 1 Flow diagram of subjects through each stage of the study.
We studied the prevalence of atopic sensitization and related clinical conditions in marathon runners and investigated the effects of probiotic supplementation during pollen season and during the marathon.
Methods Participants
Marathon runners planning to attend the 2003 Helsinki City Marathon (HCM) were recruited through an invitation letter sent to the former HCM participants and a call on a national runner's magazine. Runners were included if their personal best marathon time for women was less than 3 h 40 min and for men less than 3 h 30 min. Exclusion criteria included use of antibiotics 2 months prior to the study, pregnancy, lactation, gastrointestinal diseases and medication for them and acute gastrointestinal disorders 2 months prior to the study. All provided informed consent and the study was approved by the Ethics Committee of Hospital District of Helsinki and Uusimaa.
Athletes answered to a structured questionnaire that included specific allergy and asthma questions. Athletes were considered to suffer from asthma, rhinitis, conjunctivitis, atopic dermatitis or food allergy, if the diagnosis had been made by a physician. Atopy was defined by specific IgE to any of the allergens tested (see below).
Intervention
The study was a randomized, double-blind, placebo-controlled trial, which took place between April and August 2003. After a 4-week run-in period, subjects were allocated according to computer-generated block randomization, to receive either Lactobacillus rhamnosus GG (LGG) (ATCC53103) or placebo containing milk-based fruit drink supplied by Valio Ltd., Helsinki, Finland.
LGG drink contained LGG 3.0 Â 10E8 cfu/ml. Subjects were asked to drink two 65 ml bottles of LGG or placebo drink per day. The 
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Outcome measurements
Blood samples were collected at (1) baseline (Train 1) 3 months before the marathon, (2) 1 week prior to the marathon (Train 2), (3) just before the marathon (Run 1), and (4) 
Statistical analysis
All analyses were conducted using the ''intention-to-treat'' approach, including all randomized athletes who took at least one dose of the study preparation and who had at least one postbaseline efficacy variable measurement. The ITT analyses were used for all efficacy measures. Missing data for those who withdrew from the study before its completion or from whom data was missing for reasons unrelated to treatment were estimated using an expectation-maximization algorithm. Overall, data was imputed in 5.9% (70/1182) of the samples (60/644 for the training period and 10/538 for the marathon). Because of their skewed distributions, all comparisons were made after logarithmic transformation.
To permit analysis in the log scale, a constant (0.1) was added to each value of the percent eosinophil count to eliminate 0 values. Baseline characteristics were compared using Fisher exact test for categorical variables or Student's test for numeric variables; changes within groups were compared using paired t-test and differences between placebo and LGG groups were compared by analysis of covariance (ANCOVA) with baseline value (Train 1 or Run 1) as covariate. Values of po0:05 were regarded as significant. No adjustment was made for multiple testing, but this information can be obtained by multiplying the actual p value by the number of comparisons made. 
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Results
Of the 144 volunteers recruited to the study, 141 fulfilled the entry criteria and were randomized. Two subjects withdrew before starting the intervention and were excluded from the analysis (Fig. 1) .
Prevalence of asthma and allergy
Physician-diagnosed asthma was reported by 6 (4.3%) and allergic rhinitis by 24 (17.3%) athletes ( Fig. 2 ) or between the atopic (Phadiatop spositive) or non-atopic runners during the training period (Table 3 ). In the 35 atopic runners, total serum IgE and Phadiatop s increased but blood eosinophil numbers or serum ECP did not change.
Effect of LGG during 1 week prior to and during marathon run
In all runners, the number of blood eosinophils and serum ECP levels decreased significantly during the week preceding the run. In atopic runners, total IgE increased significantly. No differences in changes were observed between the LGG or placebo groups during 1 week before the run (Table 4) .
In all runners, the marathon run induced a significant eosinopenia, but serum ECP did not change. In atopic runners, similar eosinopenia was observed as in the whole group. The marathon run did not affect total IgE of the atopic runners. The responses to the marathon run were similar in the LGG and placebo groups (Table 5 , Fig. 2 ). LGG, n=20 Placebo, n=15
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Discussion
Asthma is diagnosed more frequently in elite athletes than in the general population. 4, [13] [14] [15] [16] Atopy and type of sports appear to be the two major risk factors; atopic long distance runners had a 42-fold increased risk of asthma compared to non-atopic non-athletes. 17 We observed a 4.3% prevalence of physician-diagnosed asthma in non-elite athletes. This is close to asthma prevalence in the Finnish general population (between 5.5% and 6.6%). 18, 19 Of the runners, 88% were male, and asthma prevalence of 5.1% of Finnish males has been reported. 18 In a sample of 71 Finnish long distance runners, 7.0% had asthma. 17 Of 108 endurance athletes supported by the Finnish National Olympic Committee, and of 103 athletes from Finnish national teams, 22.2% 20 and 16%, respectively, had asthma. 13 The increased figures of asthma prevalence in high level competitive athletes have been attributed to an irritant-induced airway inflammation and bronchial hyperreactivity, 2, 6, 21 which have attenuated after discontinuing training and competition. 2 The relatively low prevalence of asthma in our athletes may reflect a ''healthy runner effect''. Our subjects were non-elite runners, and individuals having symptoms suggestive of asthma do not easily continue long-distance running; they may change their hobby to other types of sports. The prevalence of allergic rhinitis in athletes, assessed by the questionnaire has varied from 16.8% to 41% 4, 14, 15, [22] [23] [24] [25] [26] while the prevalence of allergic rhinitis in Finnish population ranges from 26% to 36%. 18 The prevalence of allergic rhinitis (17.3%) in the present study is close to the figures of the general population. In contrast, the prevalence of allergic conjunctivitis (2.9%) was low, although similar to another study (3.6%) of athletes. 26 Athletes conjunctivas are not exposed to such an increased amount of airborne allergens than airway mucosa due to a high ventilation rate. The overall prevalence of atopy (31%) was similar to the figure previously reported in Finnish longdistance runners (33.8%). 17 Sensitization rates to birch, timothy, mugwort, D. pteronyssinus and C. herbarum were almost coincident with those reported for Helsinki adult population, 27 not suggesting an increased risk of sensitization in non-elite runners. In Finland, between 1994 and 2000, the use of asthma medication increased 42% to a figure near 5% of the general population. 28 However, the use of asthma medication has been four times more frequent (22%) in Finnish elite long-distance runners. 17 In the present study, the frequency of reported asthma medication (2.9%) was close to figures in the general population.
During the training period, the main pollen season in Finland, we observed: (1) an increase of serum ECP in all athletes, and of total IgE and Phadiatop s in the atopics, and (2) LGG intake had no effect on this variation neither in atopic nor in non-atopic athletes.
Higher levels of ECP during the birch pollen season in healthy subjects have been reported but remain unexplained. 29 Exposure to pollen proteases in vitro causes concentration-dependent detachment of airway epithelial cells. 30 Disruption of the epithelial barrier by proteases in pollens might thus occur in some subjects when training outdoor, with high ventilation rates during the pollen season, contributing to a low-grade systemic inflammation.
Although probiotic supplementation may have a role in prevention and management of allergic eczema, 10, 11, 31 only 32 In a food allergy model, the intraperitoneal injection of Lactobacillus casei strain Shirota to OVA-TCR-Tg mice-induced suppression of IgE, IgG1 and systemic allergic reactions. 33 L. casei induced IFN-gamma, but inhibited IL-4 and IL-5 secretion, and markedly suppressed total and antigenspecific IgE secretion by OVA-stimulated splenocytes obtained from OVA-primed BALB/c mice. 34 Probiotics may regulate IL-4 and IL-5 expression 35 and affect eosinophil development and activation. In human studies, a trend to decrease blood eosinophils was noticed after L. acidophilus supplementation to asthma patients. 36, 37 Our findings do not support probiotic supplementation during pollen season in reducing the seasonal increase of IgE response in runners, but do not rule out possible beneficial effects of probiotics in other type of sports, e.g. in cold air sports or swimming.
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Pre-competitive stress and stop of heavy training during the week preceding the marathon could play a major role in the decrease of ECP and blood eosinophils. Acute exercise has increased numbers of neutrophils and monocytes and decreased lymphocytes in cell counts. 7 Changes in eosinophils after marathon or strenuous exercise have been reported with conflicting results. Nieman et al. 38 reported eosinopenia in 10 marathoners after a 3 h run in a laboratory setting; the eosinopenia was maintained for at least 21 h. In another study, cell counts and ECP from seven athletes swimming 5-km were unaffected. 39 Increase in serum cortisol levels seen after a marathon may have a role in the observed marathon-induced eosinopenia. 7 LGG did not prevent the eosinopenia.
We conclude that in non-elite long-distance runners, prevalence of allergic diseases is similar to the general population.
LGG did not affect the allergic markers during the training period or the marathon race.
